In a small cell lung cancer (SCLC) mouse model, circRNA-CAR-T treatment increased tumor-infiltrating T cells (Lasvergnas et al., 2022), decreased exhausted T cells (PD-1+TIM-3+) by 50%, and significantly extended median survival. Here, HAVCR2 is linked to small cell lung carcinoma.